KS risk group and HAART therapy in patients with KS responses
Patient no. . | IL-12, ng/kg . | Tumor risk category (T)* . | Symptom risk category (S) . | HAART at entry, wk . | Weeks to first PR . | HAART at PR, wk . | ART change prior to response . |
|---|---|---|---|---|---|---|---|
| 1 | 300 | 1 | 0 | 12 | 52 | 64 | No |
| 2 | 300 | 1 | 0 | 87 | 18 | 105 | No |
| 3 | 300 | 1 | 1 | NA† | 12 | NA† | No |
| 4 | 300 | 1 | 1 | 44 | 16 | 60 | No |
| 5 | 300 | 1 | 1 | 14 | 8 | 21 | No |
| 6 | 300 | 1 | 1 | 207 | 36 | 243 | Yes‡ |
| 7 | 500 | 1 | 0 | 23 | 56 | 79 | No |
| 8 | 500 | 1 | 0 | 113 | 52 | 165 | No |
| 9 | 500 | 1 | 0 | 12 | 8 | 20 | No |
| 10 | 500 | 1 | 0 | 169 | 36 | 205 | No |
| 11 | 500 | 1 | 0 | 38 | 26 | 64 | Yes‡ |
| 12 | 500 | 1 | 0 | 16 | 8 | 24 | No |
| 13 | 500 | 0 | 0 | 82 | 16 | 98 | Yes‡ |
| 14 | 500 | 1 | 1 | 113 | 28 | 141 | No |
| 15 | 500 | 1 | 1 | 78 | 6 | 84 | No |
| 16 | 625 | 0 | 0 | 142 | 24 | 166 | No |
| 17 | 625 | 0 | 0 | 176 | 12 | 188 | No |
Patient no. . | IL-12, ng/kg . | Tumor risk category (T)* . | Symptom risk category (S) . | HAART at entry, wk . | Weeks to first PR . | HAART at PR, wk . | ART change prior to response . |
|---|---|---|---|---|---|---|---|
| 1 | 300 | 1 | 0 | 12 | 52 | 64 | No |
| 2 | 300 | 1 | 0 | 87 | 18 | 105 | No |
| 3 | 300 | 1 | 1 | NA† | 12 | NA† | No |
| 4 | 300 | 1 | 1 | 44 | 16 | 60 | No |
| 5 | 300 | 1 | 1 | 14 | 8 | 21 | No |
| 6 | 300 | 1 | 1 | 207 | 36 | 243 | Yes‡ |
| 7 | 500 | 1 | 0 | 23 | 56 | 79 | No |
| 8 | 500 | 1 | 0 | 113 | 52 | 165 | No |
| 9 | 500 | 1 | 0 | 12 | 8 | 20 | No |
| 10 | 500 | 1 | 0 | 169 | 36 | 205 | No |
| 11 | 500 | 1 | 0 | 38 | 26 | 64 | Yes‡ |
| 12 | 500 | 1 | 0 | 16 | 8 | 24 | No |
| 13 | 500 | 0 | 0 | 82 | 16 | 98 | Yes‡ |
| 14 | 500 | 1 | 1 | 113 | 28 | 141 | No |
| 15 | 500 | 1 | 1 | 78 | 6 | 84 | No |
| 16 | 625 | 0 | 0 | 142 | 24 | 166 | No |
| 17 | 625 | 0 | 0 | 176 | 12 | 188 | No |
HAART indicates highly active antiretroviral therapy; PR, partial response; ART, antiretroviral therapy; and NA, not applicable.
Of the patients who were scored as T1, 8 had edema of the legs or feet, 1 had ulcerative KS lesions of the feet, 1 had pulmonary KS, 1 had oral KS, and 4 had a history of oral KS (1 patient) or visceral KS (3 patients, 1 each with pulmonary, gastrointestinal, and extensive oral involvement).
Patient 3 had been on dual nucleoside anti-HIV therapy with stavudine and lamivudine for 43 weeks at entry and remained on this therapy until he had a PR at week 12.
Patient 6 had his dose of saquinavir increased 2 weeks after entry and then changed to fortovase; KS response patient 11 had his HAART regimen changed 5 weeks before he had a PR; KS response patient 13 had the zidovudine in his HAART regimen changed to stavudine because of anemia 4 weeks before he had a PR.